Exclusive: Feng Zhang’s epigenetic editing startup shifts focus to siRNA obesity therapies - Endpoints News
Moonwalk Biosciences, founded by Feng Zhang and Alex Aravanis, shifts from epigenetic editing to siRNA drugs, targeting obesity through adipose tissue manipulation.
Comments